» Articles » PMID: 23953755

Schizophrenia and the Risk of Cardiovascular Diseases: a Meta-analysis of Thirteen Cohort Studies

Overview
Journal J Psychiatr Res
Specialty Psychiatry
Date 2013 Aug 20
PMID 23953755
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Numerous studies have investigated the relationship between schizophrenia and the incidence of cardiovascular disease (CVD), but their results were not entirely consistent. Our study aimed to elucidate the association between schizophrenia and the risk of CVD by a meta-analysis of cohort studies.

Methods: PubMed, the Cochrane Library, and EMBASE databases were searched to identify relevant studies that met the prespecified inclusion criteria. We also reviewed reference lists from the retrieved articles. Relative risks (RRs) and 95% confidence intervals (CIs) were extracted and pooled using the fixed-effect or random-effects models.

Results: Thirteen studies involving 3,549,950 participants, with outcomes of CVD reported for 422,698, were included in the meta-analysis. The follow-up period ranged from 1.6 to 36.0 years. The meta-analysis found that the pooled RRs for schizophrenia compared with the reference group were 1.53 (95% CI: 1.27-1.86) for the incidence of CVD, 1.20 (95% CI: 0.93-1.53) for coronary heart disease (CHD), 1.71 (95% CI: 1.19-2.46) for stroke, and 1.81 (95% CI: 1.42-2.29) for congestive heart failure (CHF). Sensitivity analysis after the exclusion of a single cohort or using the unadjusted RRs yielded similar results to the primary overall estimations. No evidence of publication bias was observed.

Conclusions: Schizophrenia is associated with increased incidence of CVD, stroke and CHF, and might also increase the risk of CHD. Greater attention should be paid to schizophrenia patients to prevent the occurrence of CVD and to decrease the risk of cardiac morbidity.

Citing Articles

QT Interval, Antipsychotics and Correlates Among Patients with Schizophrenia: Cross-Sectional Data from the Multicentric Real-World FACE-SZ.

Gerentes M, Lajnef M, Szoke A, Aouizerate B, Berna F, Clery M Drug Saf. 2025; .

PMID: 40088341 DOI: 10.1007/s40264-025-01526-9.


Cardiovascular comorbidities in Chinese inpatients with schizophrenia spectrum disorders.

Dong Z, Wu G, Liu H, Chen S, Bi B, Zhang F Schizophrenia (Heidelb). 2025; 11(1):22.

PMID: 39971916 PMC: 11840127. DOI: 10.1038/s41537-025-00576-3.


Drugs used in psychiatry causing an increase in body weight in children-a review.

Kuzbicka K, Pawlowska I, Kocic I Int J Obes (Lond). 2024; .

PMID: 39448870 DOI: 10.1038/s41366-024-01662-9.


Comorbid health outcomes in patients with schizophrenia: an umbrella review of systematic reviews and meta-analyses.

Lee H, Lee J, Lee S, Lim J, Kim H, Park J Mol Psychiatry. 2024; 30(3):1127-1137.

PMID: 39424931 DOI: 10.1038/s41380-024-02792-2.


Polygenic Resilience Scores are Associated with Lower Penetrance of Schizophrenia Risk Genes, Protection Against Psychiatric and Medical Disorders, and Enhanced Mental Well-Being and Cognition.

Hess J, Barnett E, Hou J, Faraone S, Glatt S medRxiv. 2024; .

PMID: 38883801 PMC: 11177905. DOI: 10.1101/2024.06.03.24308377.